WATERTOWN, Mass., Jan. 20, 2022 /PRNewswire/ — Windgap Medical, Inc., a leading specialty pharmaceutical and drug delivery platform company, announced today that it has successfully completed its final close with over $39 million of Series B-1 equity financing, led by Taiwania Capital. This equity round of investment expanded beyond an initial target of approximately $32 million due to strong investor interest. This equity financing is also supported by existing investors, including Shepherd Kaplan Krochuk (SKK) and Molex Ventures (a Koch Industries company), along with new investors including Cobro Ventures, and others.
Windgap is working to commercialize its ANDI® wet/dry autoinjector platform, which would introduce a more compact, stable, temperature-resilient option for many medications currently in the marketplace. The first product to use this platform will be epinephrine for the treatment of anaphylaxis. Other pipeline products include a novel emergency treatment for cyanide poisoning that is sponsored by the National Institutes of Health through a multi-year CounterACT grant, led by the University of Minnesota Twin Cities.